Palvella Therapeutics (NASDAQ:PVLA) Stock Gets Price Target Reduction from HC Wainwright

Posted by Francis Steltz on Oct 15th, 2026

Palvella Therapeutics (NASDAQ:PVLA – Free Report) had its target price cut by HC Wainwright from $270.00 to $246.00 in a report issued on Monday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2027 earnings at ($13.52) EPS, FY2028 earnings at ($10.40) EPS, FY2029 earnings at ($4.84) EPS and FY2030 earnings at $5.82 EPS.

Several other analysts have also recently weighed in on the company. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a report on Wednesday, August 5th. Chardan Capital assumed coverage on Palvella Therapeutics in a research report on Monday, September 21st. They set a “buy” rating and a $240.00 price target for the company. Truist Financial set a $207.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $207.43.

Check Out Our Latest Stock Report on PVLA

Palvella Therapeutics Trading Down 4.6%

Shares of PVLA stock opened at $122.58 on Monday. Palvella Therapeutics has a 52-week low of $68.96 and a 52-week high of $161.38. The business’s fifty day moving average is $146.74 and its 200 day moving average is $134.32.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.35). As a group, equities research analysts predict that Palvella Therapeutics will post -6.40 earnings per share for the current year.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $152.24, for a total transaction of $654,936.48. Following the completion of the sale, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at approximately $327,924.96. The trade was a 66.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher P. Kiritsy sold 313 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $157.00, for a total transaction of $49,141.00. Following the completion of the transaction, the director owned 250 shares of the company’s stock, valued at $39,250. This trade represents a 55.60% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 56,743 shares of company stock worth $8,219,632. 17.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Palvella Therapeutics

A number of large investors have recently added to or reduced their stakes in PVLA. Bank of America Corp DE lifted its stake in Palvella Therapeutics by 25.4% during the first quarter. Bank of America Corp DE now owns 37,972 shares of the company’s stock worth $4,733,000 after purchasing an additional 7,700 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Palvella Therapeutics by 688.9% in the 1st quarter. The Manufacturers Life Insurance Company now owns 17,907 shares of the company’s stock worth $2,232,000 after purchasing an additional 15,637 shares in the last quarter. Blue Owl Capital Holdings LP bought a new position in shares of Palvella Therapeutics during the 2nd quarter valued at about $5,541,000. Deutsche Bank AG bought a new position in shares of Palvella Therapeutics during the 2nd quarter valued at about $1,809,000. Finally, Emerald Mutual Fund Advisers Trust bought a new position in shares of Palvella Therapeutics during the 1st quarter valued at about $13,190,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics News Roundup

Here are the key news stories impacting Palvella Therapeutics this week:

Positive Sentiment: HC Wainwright maintained a Buy rating and $246 price target. Despite lowering its earnings forecasts, the analyst’s target remains well above recent trading levels, indicating continued confidence in Palvella’s longer-term opportunity. HC Wainwright analyst coverage
Neutral Sentiment: Management will participate in the Chardan 10th Annual Healthcare Conference on October 20. The fireside chat could provide updates on Palvella’s development programs for rare skin diseases and vascular anomalies, although no new clinical or regulatory information was announced. Palvella Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference
Negative Sentiment: HC Wainwright significantly reduced its projected earnings for 2027 through 2030. Estimates were cut to losses of $13.52 per share in 2027, $10.40 in 2028 and $4.84 in 2029, while the 2030 forecast was reduced to $5.82 from $19.10. The revisions suggest a slower path to profitability and likely contributed to the stock’s decline.
Negative Sentiment: Director George Jenkins sold 20,326 shares worth approximately $2.69 million across October 12 and 13. The transactions reduced his direct ownership by roughly 13% overall. Both sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which may lessen their significance, but the sizable insider selling can still weigh on investor sentiment. Palvella Therapeutics SEC insider transaction filing

Palvella Therapeutics Company Profile

(Get Free Report)

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.